Tuesday, September 02, 2008

Biogen Testing Regenerative Medicine Drug to Reverse Multiple Sclerosis - Studies suggest underlying pathology different between different formsof MS

Diagnosis and Types of MS

primary progressive MS



Dr. Yeung

Director MS Clinical Trials Research Unit Foothills MS Clinic, Calgary


View BIO


Q :


In the interview with Dr. Owens in MS Canada, he stated, that primary progressive MS "seems to be a disease with a different primary cause" and although the cause is unknown "it looks and feels like a different disease". Could someone expand on the latter statement? It is so difficult to obtain information on primary-progressive that any information is most welcome.
A :


There are four clinical patterns of multiple sclerosis: relapsing remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). Definitions of these can be found on the MS Society website by clicking here.
About 85% of patients with MS have relapsing remitting multiple sclerosis (RRMS). This is characterized by exacerbations (episodes of neurological dysfunction such as paralysis, optic neuritis, numbness, etc.) with or without complete recovery. They are clinically stable between attacks. This form is most common in young women, and the disease can be treated with the immunomodulatory therapies (interferon-betas, glatiramer acetate, mitoxantrone, and natalizumab).

In primary progressive multiple sclerosis (PPMS), there is gradual progression of disability (neurological symptoms progress without recovery) from onset without superimposed relapses; this occurs in ~10% of MS patients. There is a preponderance in middle-aged men, and the immunomodulatory treatments seem to have no effect; the mainstay of treatment is management of symptoms. There have also been some studies suggesting the underlying pathology may be different between the different forms of MS; the reason for this is currently unknown and further research is underway.
Because of these differences, it is possible that "multiple sclerosis" is an umbrella term, and that the different clinical forms align along a spectrum under that umbrella. Further clarification from future studies is necessary to delineate this further.
9/2/2008 3:03:11 AM
More answers from Dr. Michael Yeung
More answers in the category: Diagnosis and Types of MS

DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
© 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca

http://www.msanswers.ca/QuestionView.aspx?L=2&QID=1291



Update on Relapsing-Remitting MS: B-cell Depletion with Rituximab
IIn this article review, Dr. Bruce Cree comments on a recent clinical trial that explored the use of rituximab, a monoclonal antibody directed against CD20+ B lymphocytes, as therapy for patients with multiple sclerosis.

Life Sciences 25
Boston Globe - United States
Biogen Idec gave a positive update on two Tysabri patients suffering from a potentially fatal side effect; a judge reduced a patent award against Boston ...

Preventive migraine therapy with a proven safety profile
Looking for a different treatment option for migraine patients? Consider the #1 medication prescribed by neurologists for migraine prevention1. Click to learn more about a treatment option with a proven safety profile. 1.IMS Health January 2008 . Source: Ortho-McNeil Neurologics [more]

Do drugs prevent the progression into secondary progressive MS?


Dr. Schapiro

Clinical Professor of Neurology


View BIO


Q :


It seems that 90% of people with relapsing remitting MS develop secondary progressive MS in time. What is the currently available data on the effects of beta-interferon or glatiramer acetate? Do these drugs delay the time of onset of the transformation? Do they prevent the progression into secondary progressive MS?

A :

The data that 90% of people with relapsing MS develop secondary progressive MS is to be questioned. The reality is that when the population is sampled at any one time 55% have relapsing MS and 33% have secondary progressive.


If 90% developed secondary progressive it would change the number of those with that diagnosis greatly over time and it simply doesn't. That number comes from a misinterpretation of old natural history data and the desire to scare people onto therapy instead of being reasonable and understanding.

The other issue is that studies on immune modulating medication are relatively short. That is out of practical necessity. However each medication has attempted to get long term data and in every case there is a clear difference made by treatment. Thus it seems reasonable to assume that these medications have made a major difference in delaying the time to transformation (even if the transformation had been previously exaggerated).

They certainly delay the progression if not prevent it in many but clearly not all. I usually answer this by pointing out I used to have a floor in the hospital devoted to MS with 18 patients hospitalized daily. Now I have 1-2 in the hospital at any one time. That is quite a difference and the reason appears to be treatment oriented.
9/2/2008 3:20:11 AM
More answers from Dr. Randall T. Schapiro
More answers in the category: Treatment

DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
© 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca

http://www.msanswers.ca/QuestionView.aspx?L=2&QID=1605





Source:
Projects In Knowledge [more] ESC: Statin Flops While Fish Oil Supplement Floats in Chronic Heart Failure
MUNICH -- A fish oil capsule atop standard therapy for chronic heart failure significantly reduced mortality and hospital admissions whereas a potent statin had no comparable benefits, researchers reported here. full story

http://www.medpagetoday.com/MeetingCoverage/ESCCongress/tb/10733

Campaign ’08: Obama Wraps Up Convention with Promise of Better Healthcare
DENVER -- Barack Obama laid out a bare-bones sampling of his healthcare plan as he accepted the presidential nomination of the Democratic National Convention. full story

http://www.medpagetoday.com/Campaign08/Campaign08/tb/10717

Preventive migraine therapy with a proven safety profile
Looking for a different treatment option for migraine patients? Consider the #1 medication prescribed by neurologists for migraine prevention1. Click to learn more about a treatment option with a proven safety profile. 1.IMS Health January 2008 . Source: Ortho-McNeil Neurologics [more]

Cellular research holds promise for diabetes
Honolulu Star-Bulletin - Honolulu,HI,USA
... blood sugar levels fell to near-normal. The study's senior researcher has strong motivation to seek new treatment. His children have Type 1 diabetes.


0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home